← Leaderboards
Jeffrey D Chulay
Alphavax Human Vaccines, Inc.
$16,245,998
Attributed
$16,245,998
Total exposure
5
Grants
4
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $1.8M · FY2005–13$2M$1.5M$1M$500K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
Funding mix
By agency
NIH$14,111,762 · 3
FDA$2,134,236 · 2
By mechanism
U01$13,968,680 · 2
R01$2,134,236 · 2
R43$143,082 · 1
Top collaborators
No co-investigators on record.
Most similar at Alphavax Human Vaccines, Inc.
Same institution · by research overlap
- Jonathan Smith$21,963,803
- Robert A. Olmsted$878,891
Others in their field
Top investigators on “Vaccine Development”
- Lawrence Corey · Fred Hutchinson Cancer Center$718,120,301
- Margaret Juliana McElrath · Fred Hutchinson Cancer Center$554,939,981
- Bambra Strokes · Ppd Development Lp$526,656,217
- Barton F Haynes · Duke University$394,383,754
- Glenda E Gray · Wits Health Consortium (Pty), Ltd$392,263,550
- Dennis R. Burton · Scripps Research Institute$312,611,400
Research focus
Vaccine DevelopmentVector VaccineRepliconAlphavirusBiotechnologyCooperative StudySerotypingEnzyme Linked Immunosorbent AssayDrug Screening /EvaluationBioterrorism /Chemical WarfareLaboratory MouseClinical Trial Phase ISds Polyacrylamide Gel ElectrophoresisBacterial VaccinesClinical ResearchPolymerase Chain ReactionNonhuman Therapy EvaluationElectroporationBotulinum ToxinsPatient Oriented ResearchAids VaccinesNeutralizing AntibodyHuman SubjectAffinity Chromatography
Grant awards (15)
Phase 2 Study of rAAV1-CB-hAAT for Treatment of Alpha-1 Antitrypsin Deficiency$98,066
R01 · FY2013 · FD · contact PI
Phase 1/2 Trial of rAAV2-CB-hRPE65 (BB-IND 13848, 11 Sep 2009) for Leber Congenit$59,169
R01 · FY2013 · FD · contact PI
Phase 1/2 Trial of rAAV2-CB-hRPE65 (BB-IND 13848, 11 Sep 2009) for Leber Congenit$252,411
R01 · FY2012 · FD · contact PI
Phase 2 Study of rAAV1-CB-hAAT for Treatment of Alpha-1 Antitrypsin Deficiency$139,545
R01 · FY2012 · FD · contact PI
Phase 2 Study of rAAV1-CB-hAAT for Treatment of Alpha-1 Antitrypsin Deficiency$400,000
R01 · FY2011 · FD · contact PI
Phase 1/2 Trial of rAAV2-CB-hRPE65 (BB-IND 13848, 11 Sep 2009) for Leber Congenit$385,045
R01 · FY2011 · FD · contact PI
Phase 1/2 Trial of rAAV2-CB-hRPE65 (BB-IND 13848, 11 Sep 2009) for Leber Congenit$400,000
R01 · FY2010 · FD · contact PI
Phase 2 Study of rAAV1-CB-hAAT for Treatment of Alpha-1 Antitrypsin Deficiency$400,000
R01 · FY2010 · FD · contact PI
rAAV5-hCNGB3 Gene Therapy for Achromatopsia: Efficacy in a Dog Model$143,082
R43 · FY2010 · EY · contact PI
Alphavirus Replicon Vaccines against Botulinum Neurotox*$1,448,108
U01 · FY2006 · AI · contact PI
Alphavirus Replicon Vaccines against Botulinum Neurotox*$1,799,459
U01 · FY2005 · AI
Alphavirus Replicon Vaccines against Botulinum Neurotox*$3,577,242
U01 · FY2004 · AI
HIV Subtype C Alphavirus Vaccine Design &Development$3,529,060
U01 · FY2003 · AI
Alphavirus Replicon Vaccines against Botulinum Neurotox*$1,344,570
U01 · FY2003 · AI
HIV Subtype C Alphavirus Vaccine Design &Development$2,270,241
U01 · FY2002 · AI